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Abstract
Little is known about polyclonal peripheral blood plasmacytosis in dengue virus (DENV)-infected patients. We initiated this prospective
observational study to quantify and describe the kinetics and phenotype of peripheral blood plasma cells (PCs) in these patients. Mor-
phological examination and ﬂow cytometric (FC) analysis for the characterization and immunophenotyping of lymphocyte subsets and
PCs were performed in 35 and 31 patients suspected of DENV infection, respectively. Our results show that blood plasmacytosis is a
very common haematological ﬁnding. Depending on the days of illness at presentation, blood plasmacytosis was observed in 64%
to 73% of patients. Blood plasmacytosis was most pronounced before 7 days of illness and declined rapidly thereafter, to completely
disappear after 14 days of illness. Blood plasmacytosis was higher in secondary DENV infection. The majority of CD138+ PCs (89%) had
a shared immunophenotype (CD45+/CD19)/CD56)) and in all cases the PCs were polyclonal. Blood plasmacytosis, characterized by a
transient presence of polyclonal PCs in the circulation, is a common event in DENV infection.
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Introduction
Dengue is an infectious disease that is caused by dengue virus
(DENV). DENV transmission takes place through bites by
Aedes mosquito vectors. There are four DENV serotypes,
which, based on antigenic and genetic differences, could be
regarded as four distinct virus species (DENV1–4). All sero-
types are capable of infecting and replicating in numerous
human cells, including dendritic cells, monocytes/macrophages,
B cells, T cells, endothelial cells, hepatocytes and neuronal
cells in vivo. Although a consensus that the mononuclear
phagocyte lineage cells constitute the primary targets for repli-
cation based on clinical and autopsy studies, there is still con-
troversy about the primary cell type(s) targeted in humans [1].
Infection by one of the four DENV serotypes cannot be
distinguished on clinical grounds; clinical manifestations vary
from mild undifferentiated febrile illness to severe dengue,
including dengue haemorrhagic fever (DHF) and dengue
shock syndrome (DSS), of which the latter is the most life
threatening [2]. One of the characteristic features of dengue
is the occurrence of leucopenia and thrombocytopenia,
probably resulting from virus-induced bone marrow suppres-
sion [3]. This is non-speciﬁc and not exclusively seen in den-
gue. Thrombocytopenia may worsen as a result of
coagulopathy and vasculopathy in patients with severe dis-
ease. Despite the general bone marrow suppression, blood
plasmacytosis has been reported in a few patients with
DENV infection [4,5]. However, the frequency of blood plas-
macytosis in patients with dengue infection, the origin of
these plasma cells (PCs) and the mechanisms by which they
appear in the blood are not known.
Blood plasmacytosis is an unusual haematological ﬁnding
that is most commonly seen in plasma cell leukaemia or
advanced stage multiple myeloma, in which case the plasma
cells are part of the malignant clone and thus are mono-
clonal. Non-malignant reactive peripheral plasmacytosis is
occasionally found in a variety of diseases, such as tumours,
autoimmune disorders, and infectious diseases including
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sepsis, primary infection and reactivation of Epstein–Barr
virus, acute respiratory infections, parvovirus B19 infection,
rubella and hepatitis virus A infection [6–11].
In this study, we prospectively quantiﬁed and described
blood plasmacytosis in returned travellers with DENV infec-
tion. We also characterized the immunological phenotype of
these PCs by ﬂow cytometry and explored associations with
viral load, the appearance of anti-DENV IgG antibodies, and
the presence of primary or secondary DENV infection.
Materials and Methods
Study site and study population
Returned travellers presenting with a history of <14 days of
fever, clinically suspected of dengue, were included at the
Department of Tropical Diseases, Academic Medical Centre,
Amsterdam, the Netherlands. Blood samples were collected
from each patient for routine diagnostic procedures. All sam-
ples were tested by enzyme-linked immunosorbent assay
(ELISA) for anti-DENV IgM and IgG antibodies and DENV
real-time reverse transcriptase polymerase chain reaction
(RT-PCR). Morphological examination and ﬂow cytometric
(FC) analysis of blood were performed within 24 h after the
blood was drawn. All patients at this department are rou-
tinely informed that their data can be used for observational
studies. All patients consented to participate in this study.
Dengue diagnostics
Serum samples were routinely tested for dengue antibodies
with direct IgG enzyme-linked immunosorbent assay
(ELISA) and IgM-Capture ELISA (Panbio Tech Co., Brisbane,
Australia). For real-time RT-PCR, RNA was isolated from
blood plasma as described elsewhere [12]. RNA was reverse
transcribed and ampliﬁed using an internally controlled
and quantitative serotype-speciﬁc, TaqMan-based assay as
described elsewhere [13]. Quantitative results were
expressed as cDNA equivalents per millilitre. The RT-PCR
and ELISA results were used for diagnosis and classiﬁcation
of dengue infection.
Classiﬁcation of primary and secondary dengue
Acute primary DENV infections were conﬁrmed by RNA
detection and/or detection of dengue-speciﬁc IgM antibodies
in acute samples, in the absence of dengue serum-speciﬁc
IgG antibodies. A negative ﬁrst acute sample for dengue
serum-speciﬁc IgM antibodies with seroconversion for IgM
antibodies within 7–14 days was also considered as primary
dengue. Acute secondary DENV infections were conﬁrmed
on acute samples (<14 days) with positive IgG results and
detection of viral RNA, either with or without detectable
dengue serum-speciﬁc IgM antibodies.
For patients who presented with both positive IgM and
IgG results in the ﬁrst acute sample, but without detectable
RNA by RT-PCR, the ratio between the IgM and IgG con-
centrations was used to distinguish primary and secondary
infections. A ratio of anti-dengue IgM to IgG of ‡1.8 was the
criterion for primary dengue infection; values lower than 1.8
were considered to indicate secondary infections [14,15].
The patients for whom the diagnosis of DENV infection was
not conﬁrmed were grouped as other febrile illness (OFI)
and included in this study as controls.
Morphological examination
A complete blood count with differential was performed on
an automated cell counter (Sysmex XE-5000; Sysmex Corpo-
ration, Kobe, Japan). Blood smears were ﬁxed and stained
ﬁrst with May-Gru¨nwald–Giemsa eosine-methylene blue and
then, after rinsing, with Giemsa’s azur eosine methylene blue
solution (Merck Darmstadt, Germany). One hundred white
blood cells per slide were scored by one experienced techni-
cian blinded for disease outcome with a binocular micro-
scope at ·100 magniﬁcation. Lymphocytes were scored as
normal lymphocytes, atypical lymphocytes (with abundant
cytoplasm), plasmacytoid lymphocytes or PCs.
Flow cytometry analysis of peripheral blood
Erythrocytes were lysed using ammonium chloride and
washed twice with phosphate-buffered saline. Thereafter, the
cell suspension (100 lL) was mixed in tubes with 5 lL of
undiluted monoclonal antibodies (mAbs) conjugated with
ﬂuorescein isothiocynate (FITC), phycoerythrin (PE), R-phy-
coerythrin coupled to the cyanine dye Cy5 (PE Cy5),
R-phycoerythrin coupled to the cyanine dye Cy7 (PE Cy7),
allophycocyanine (APC), allophycocyanine coupled to the
cyanine dye H7 (APC-H7) and Horizon or Anemonia
Majano cyanine (AmCyan) for the following cell surface
markers: CD3, CD5, CD8, CD10, CD14, CD19, CD45,
kappa and lambda lights chains F(ab¢)2 (DAKO A/S, Glostrup,
Denmark), CD4 (Sanquin, Amsterdam, the Netherlands)
CD138 and CD16/56 (Immuno Quality Products, Groningen,
the Netherlands) in a four-tube assay. After adding the
mAbs, the cells were incubated in the dark for 15 min at
room temperature. Fluorescence intensity was determined
with an eight-colour FACSCanto (BD Biosciences, San
Jose, CA, USA) ﬂow cytometer. Mononuclear cells were
gated on the basis of forward and side light-scattering prop-
erties and subtyped on the basis of cluster of differentiation
(CD) molecule expression. Isotype-matched control mAbs
were used to deﬁne background ﬂuorescence. On average,
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1 · 104 events were acquired and analysed using CellQuest
software (BD Biosciences). For demonstration of PCs a
lower limit of detection of 0.2% of cells expressing the sur-
face marker CD138 was applied.
Statistical analysis
Statistical calculations were performed using SPSS (version
17.0; SPSS Inc., Illinois, USA). Results were summarized in
terms of medians and ranges for continuous data and non-
parametric tests were used for comparisons within groups.
For dichotomous variables, Fisher’s exact test was per-
formed. The Mann–Whitney test was used for non-normally
distributed variables. A two-tailed p-value £0.05 was consid-
ered to be statistically signiﬁcant.
Results
Study population
Morphological examination of the blood smears was per-
formed for 35 returned travellers with suspected DENV infec-
tion presenting at our hospital between September 2008 and
June 2009; FC analysis for immunophenotyping of PCs was
carried out for 31 of these patients. Demographic information
and travel history of the 35 returned travellers is shown in
Table 1. DENV infection was conﬁrmed in 28 of 35 patients,
of whom 15 had primary infection and 13 had secondary infec-
tion, and seven patients were classiﬁed as OFI.
From the 35 patients, 47 blood samples, collected on 0–
32 days after the onset of symptoms, were morphologically
examined. White blood count (WBC) subsets, stratiﬁed by
days after onset of symptoms are presented in Fig. 1a. Over-
all, blood plasmacytosis was demonstrated in 16/28 (57%)
returned travellers with conﬁrmed DENV infection. The fre-
quency of plasmacytosis was 73% (11/15) among patients
from whom blood was collected during the ﬁrst 7 days of ill-
ness. Among patients from whom a blood sample was col-
lected during the ﬁrst 14 days of illness (DOI), plasmacytosis
occurred in 64% (16/25). Plasmacytosis was not observed in
any of the seven patients with OFI.
Kinetics of plasmacytosis
During the ﬁrst 7 days of illness, the median plasma cell
count in DENV patients was 2.5% (25–75 interquartile range
(IR), 0–8%) of the total white blood cell count (Fig. 1a); the
median absolute plasma cell concentration was 8.4 · 107/L
(25–75 IR, 0–3.5 · 108/L). The PC distribution by days of ill-
ness, including eight patients with DENV infection for whom
sequential samples were available, is shown in Fig. 1(b,d).
Fig. 1(c) shows a typical example of a PC and plasmacytoid
lymphocyte in a patient with secondary DENV infection.
Immunophenotyes of CD138+ PCs in DENV infection
The antigen proﬁles of lymphocytes and plasma cells (CD19,
CD16/CD56, CD3, CD4, CD8 and CD138) are presented
in Fig. 2 for 25 patients with DENV infection and six patients
with OFI. The lymphocyte subsets did not differ signiﬁcantly
between patients with DENV infection and patients with
OFI, with the exception of PCs, characterized by being
CD138+. In patients with DENV infection, PCs were
detected during 15 days after onset of illness. The PCs were
polyclonal in all cases, with a mean kappa/lambda ratio of 1.3
(49.3:37.9). Subsequent immunophenotyping of PCs in the 19
patients with plasmacytosis revealed a shared phenotype: in
17/19 cases the majority of the PCs were CD138+/CD45+/
CD19)/CD56). A linear correlation was observed between
the percentage of PCs as assessed by morphology and by
ﬂow cytometry (R2 = 0.85).
Association between plasmacytosis and viral load,
anti-DENV IgG antibodies, and primary and secondary
DENV infection
Viral RNA was detectable in 18 of 28 DENV patients, of
whom 12 patients had primary and six had secondary DENV
infection. The median viral RNA levels were 1.2 · 107/mL
(25–75 IR, 1.3 · 104–1.7 · 108/mL) and 9.4 · 103 (25–75 IR,
2.6 · 103–2.7 · 104/mL) in primary and secondary DENV
infection (p 0.055, Mann–Whitney test), respectively. There
was no correlation between DENV load and the percentage
of blood PCs or blood PCs’ concentration (data not shown).
TABLE 1. Demographic data of returned travellers with
dengue virus infection
DF
(n = 28)
OFI
(n = 7)
P
Male/female 12/16 5/2 ns
Agea 39.4 (21.0–73.6) 42.8 (26.3–64.0) ns
Days ill at presentationa 5.8 (1–12) 4.7 (0–9) ns
Dengue classiﬁcation
Primary 15 –
Secondary 13 –
Serotype
DENV-1 12 –
DENV-2 3 –
DENV-3 – –
DENV-4 – –
DENV-1/DENV-2 3 –
Travel history
Africab – 1
Asiac 5 1
Central America/Caribbeand 14 4
South Americae 9 1
aMean (range).
bMauritius.
cIndonesia, Thailand, Cambodia.
dAruba, Bonaire, Curacao, Dutch Antilles and Panama.
eSuriname.
DF, dengue fever; OFI, other febrile illness; ns, not signiﬁcant.
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Morphological examination and anti-DENV IgG serology
were performed on the same day in 12 samples from 10
patients with secondary DENV infection. Fig. 3(a) shows per-
centages of PCs by anti-DENV IgG optical density ratios
(ODR) stratiﬁed by days of illness. The anti-DENV IgG ODR
increases beyond 5 days of illness, which is indicative of an
increase of anti-DENV IgG concentration in serum. A nega-
tive correlation was observed between IgG ODR and the
percentage of PCs, but this did not reach signiﬁcance
(p 0.053).
The median percentage of PCs was signiﬁcantly higher in
secondary than in primary dengue (4.5% vs. 1.0%, respec-
tively, p 0.05, Fig. 3b) when day of illness was not taken into
account. The difference was even more striking during the
ﬁrst 7 days of illness (15.0% vs. 0.0%, respectively, p 0.005).
Discussion
To our knowledge, this is the ﬁrst prospective study demon-
strating that blood plasmacytosis, characterized by a tran-
sient increased amount of polyclonal PCs in the circulation,
is a common haematological event in DENV infection. The
plasmacytosis was most pronounced during the ﬁrst week of
disease and disappeared completely within 2 weeks. The PCs
(a)
(c)
(b)
(d)
FIG. 1.White blood cell subset and the kinet-
ics of peripheral blood plasma cells in dengue
virus (DENV)-infected patients. (a) Leukocyte
proﬁle, determined by May-Gru¨nwald–Giemsa
staining, in patients with DENV infection strat-
iﬁed by days of illness. Data indicate median
and 25–75% range. L, lymphocyte; AL, atypical
lymphocyte; PL, plasmacytoid lymphocyte;
PC, plasma cell; NG, neutrophil granulocyte;
M, monocytes. No plasma cells were found in
patients with other febrile illness. (b and d)
Distribution of percentage (b) and absolute
(d) plasma cells (of total white blood cells) by
days of illness in patients with DENV infection.
The kinetics of sequential plasma cell results
in eight patients with DENV infection are
indicated by connected lines. (c) Plasma cell
(left) and plasmacytoid lymphocyte (right) in
peripheral blood of a patient with secondary
DENV infection (magniﬁcation ·100).
FIG. 2. General lymphocyte proﬁle, plasma cells clonality and plasma
cell immunophenotype in dengue virus (DENV)-infected patients.
General lymphocyte proﬁle by ﬂow cytometric analysis in patients
with DENV infection and other febrile illness, stratiﬁed by days of ill-
ness. L; lymphocyte; CD19+; B cell; CD16+/CD56+, natural killer cell;
CD3+, T cell; CD3+/CD4+, CD4+ T cell; CD3+/CD8+, CD8+ T cell;
CD138+, plasma cell. Data indicate median and 25–75% interquartile
range
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were all polyclonal by origin; the predominant immunophe-
notype was CD138+/CD45+/CD19)/CD56).
Bone marrow PCs are long-lived non-proliferating cells
generated as part of the humoral immune response to infec-
tions. Memory B cells that are activated by antigen in the
secondary lymphoid organs differentiate into plasmablasts
that migrate to the bone marrow, where they develop into
PCs [16]. In contrast to bone marrow PCs, plasmablasts are
short-lived proliferating cells and plasmablasts normally rep-
resent <0.1% of peripheral blood mononuclear cells (PBMCs)
[17]. PCs are usually not observed in peripheral blood and
non-malignant blood plasmacytosis in DENV infection thus
far has only been described in two reports [4,5]. A possible
explanation for limited reports on blood plasmacytosis in
DENV infection could be the use of automated cell counters
to determine peripheral cell populations [18,19]. A disadvan-
tage of these systems is the inability to identify PCs in blood.
Moreover, PCs are reported as atypical lymphocytes and ele-
vated counts have been demonstrated in the acute phase of
infection [20].
Circulating (CD138+) PCs can be regarded as PC progeni-
tors or early or mature PCs. The differentiation of B cells
into PCs is regulated by transcription factors and is charac-
terized by a number of changes in B-cell surface molecules.
CD19, CD20, CD21, CD22 and CD45 expression are
down-regulated, whereas CD38 and CD138 expression are
up-regulated [16]. In fact, CD138 is the only antigen that dis-
criminates plasmablasts (CD138)) from early and mature
PCs (CD138+). The surface phenotypes of PCs in the major-
ity of DENV-infected patients (89%) were CD138+/CD45+/
CD19)/CD56). This differs from bone marrow and blood
PCs from patients with reactive plasmacytosis, which are
usually CD19+ [6,20].
CD19 is a protein that is invariably present on B cell line-
age cells but is lost during maturation to plasma cells [21].
This could point to redistribution as the cause of increased
number of plasma cells in peripheral blood. However,
increased production may also play a role as CD45 is
expressed [22]. During DENV infection, virus and cytokines
are detectable in blood and PBMCs, similar to what is seen
in many other virus infections [23,24]. Both B cells and
monocytes can secrete IL-6 [25,26]. IL-6 has the ability to
prevent plasma cells from going into apoptosis and thus
increases the survival of PCs. Other cytokines than IL-6 can
also be involved in the development of plasmacytosis.
DENV-infected monocytes produce IL-1, which is a known
inducer of IL-6 and tumor necrosis factor-a and can induce
an inﬂammatory response and the maturation of B cells into
PCs [27]. Moreover, increased levels of IL-6 have been asso-
ciated with dengue disease severity, particularly in patients
with DHF and DSS [24,28,29]. Production of IL-6 is also a
common response in a variety of diseases that are not char-
acterized by blood plamacytosis. This implies that either IL-6
production is not the sole explanation for blood plasmacyto-
sis or that plasmacytosis does occur much more often than
has been hitherto recognized.
B cells and monocytes in PBMCs support virus replication
[1]. B cells contribute to dengue pathogenesis by producing
high titres of antiplatelet auto-antibodies and anti-endothelial
cell antibodies, which could induce increased vascular perme-
ability [24]. The parallel time course of DENV and peripheral
PCs, with normalization within 2 weeks after onset of symp-
toms, at the time when anti-DENV IgG antibodies started to
rise, taken together with the higher percentage of peripheral
blood PCs in secondary DENV infection, suggests that excess
stimulation of B cells and excess proliferation or release of
PCs play an important role in the pathogenesis of severe
dengue infection.
Although our study provides insight into the biology and
kinetics of blood plasmacytosis in DENV infection, the mech-
anism and possible role in dengue pathogenesis remain
unclear. Important unanswered questions in this respect are
(a) (b)
FIG. 3. Plasma cells, anti- dengue virus (DENV) IgG antibodies, primary and secondary DENV infection. (a) DENV serum-speciﬁc IgG antibodies
and plasma cells (by May-Gru¨nwald–Giemsa staining), by days of illness in patients with secondary DENV infection. (b) Plasmacytosis (% of total
white blood cells) in primary and secondary DENV infection by days of illness. Data indicate median and 25–75% interquartile range.
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whether active DENV replication takes place in peripheral
PCs and whether PCs are redistributed and released from
the bone marrow into the circulation. Research into these
questions can further address the contribution of peripheral
PCs to dengue pathogenesis and expand our knowledge of
DENV infection.
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